Boltz is launching a transformative approach to drug design and biological research by combining AI and open science, enabling over 100,000 scientists to innovate faster. With a newly raised $28 million seed round and a partnership with Pfizer, Boltz aims to break down barriers in drug development through open-source models and accessible computational tools.

Biomni is a versatile biomedical AI agent that utilizes large language model reasoning and retrieval-augmented planning to assist scientists in executing research tasks and generating hypotheses. It offers a comprehensive setup process, supports various API key configurations, and enables users to run tasks, generate reports, and integrate external tools. Biomni is part of an open-science initiative, encouraging community contributions to enhance its capabilities.